Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.61 |
| ▸ | FABP4 | P15090 | 1/20 | 0.61 |
| ▸ | EIF4A3 | P38919 | 5/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | FABP2 | P12104 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22358741 | 0.87 | FABP3 (0.52) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL18589751 | 0.82 | FABP3 (0.47) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL1596958 | 0.82 | CES2 (0.41) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL21977924 | 0.80 | DAO (0.44) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL21263210 | 0.78 | EIF4A3 (0.50) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL20173745 | 0.78 | EIF4A3 (0.42) | FABP3FABP4EIF4A3CYP2C9CYP2C19 | |
| SCHEMBL23657110 | 0.76 | EIF4A3 (0.41) | FABP3FABP4EIF4A3MEN1KMT2A | |
| SCHEMBL24510619 | 0.76 | EIF4A3 (0.49) | FABP3FABP4EIF4A3AKR1C3AKR1C2 | |
| SCHEMBL810177 | 0.76 | FABP3 (1.00) | FABP3FABP4EIF4A3CYP2C9HIF1A | |
| SCHEMBL26027329 | 0.76 | FABP3 (0.63) | FABP3FABP4EIF4A3PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | MIDWESTERN UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | MIDWESTERN UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | MIDWESTERN UNIVERSITY | 2020-08-20 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | ASPH, BACE1, DNPEP | FABP3 200/4885FABP4 564/4885EIF4A3 2596/4885 |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | ASPH, BACE1, DNPEP | FABP3 200/4885FABP4 564/4885EIF4A3 2596/4885 |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | ASPH, BACE1, DNPEP | FABP3 200/4885FABP4 564/4885EIF4A3 2596/4885 |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | FABP3 116/4885FABP4 610/4885EIF4A3 533/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | FABP3 530/4885FABP4 928/4885EIF4A3 1281/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | FABP3 530/4885FABP4 928/4885EIF4A3 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.